- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01686282
Blueberry Consumption Improves Vascular Function and Lowers Blood Pressure in Postmenopausal Women With Pre- and Stage 1-hypertension
Daily Incorporation of Blueberries Into a Diet Favorably Improves Vascular Function and Lowers Aortic Blood Pressure in Postmenopausal Women With Pre- and Stage 1-hypertension.
Cardiovascular disease (CVD) continues to be the leading cause of death in the U.S. Americans have been more concerned about their blood cholesterol levels and dietary cholesterol intakes rather than their overall cardiovascular health risk factors leading to CVD such as hypertension, vascular dysfunction, inadequate consumption of fruits and vegetables and physical activity. Statistics show that approximately 91% of individuals with CVD have vascular dysfunction which is attributed to endothelial and autonomic dysfunction leading to increased arterial stiffness.
The investigators long-term goal is to provide feasible and effective dietary ways for pre- and stage 1- hypertensive individuals to normalize their blood pressure (BP), improve vascular function and thereby reducing their cardiovascular risk and enhancing the quality of life. Blueberries are a rich source of phenolic compounds and these compounds may play an important role in promoting cardiovascular health. Considering the strong possibility that phytochemicals present in blueberry work additively or synergistically, it would be ideal to investigate the cardioprotective effects of blueberry as a whole. The investigators overall objective to bring forth evidence that blueberry consumption will reduce BP and cardiovascular risk factors including endothelial dysfunction, arterial stiffness, and autonomic dysfunction in pre- and stage 1-hypertensive postmenopausal women. The investigators hypothesize that blueberry supplementation will improve vascular function and will lower blood pressure in postmenopausal women with pre-hypertension. The findings of this study will provide a foundation for disseminating feasible, safe approaches for preventing and combating hypertension at its early stage which does not require drug therapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to examine the effects of 22 grams of freeze-dried blueberry intake on a daily basis for eight weeks in:
The purpose of the study is to examine the effects of 22 grams of freeze-dried blueberry intake on a daily basis for eight weeks on arterial function and blood pressure in postmenopausal women with pre- and stage 1-hypertension. The specific aims of the study are:
- To investigate the extent to which daily consumption of 22 g blueberry drink-mix reduces blood pressure in individuals with pre- and stage 1-hypertension.
- To determine whether daily consumption of 22 g blueberry drink-mix will improve the autonomic control of blood pressure and heart rate in individuals with pre- and stage 1-hypertension.
- To measure serum markers of oxidative stress to determine whether increased antioxidant defense is in part responsible for blueberry's vascular protective effects.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Tallahassee, Florida, United States, 32306
- The Department of Nutrition, Food, and Exercise Sciences, Florida State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 40 women (1 to 10 years after natural menopause or bilateral oophorectomy) 45-65 years of age.
- Seated blood pressure ≥ 130/85 mm Hg but ≤ 160/90 mm Hg.
Exclusion Criteria:
- Blood pressure >160/100 mmHg
- Taking insulin
- Cardiovascular disease
- Active cancer
- Asthma
- Glaucoma
- Thyroid disease
- Kidney disease
- Liver disease
- Pancreatic disease
- Enrollment in a weight loss program
- Heavy smokers (>20 cigarettes per day)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
8 weeks of freeze-dried blueberry powder taken in two doses of 22g each per day.
|
8 weeks of freeze-dried taken in two doses of 22g each per day.
|
Experimental: Blueberry
8 weeks of freeze-dried blueberry powder taken in two doses of 22g each per day.
|
8 weeks of freeze-dried taken in two doses of 22g each per day.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood Pressure
Time Frame: 8 weeks
|
By measuring aortic blood pressure at rest and during physiological stress (handgrip exercise and post-exercise muscle ischemia).
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Autonomic Control of Blood Pressure
Time Frame: 8 weeks
|
By measuring blood pressure variability and baroreflex sensitivity at rest and during physiological stress.
|
8 weeks
|
Autonomic Control of Heart Rate
Time Frame: 8 weeks
|
By measuring heart rate variability at rest and during physiological stress.
|
8 weeks
|
Endothelial Function
Time Frame: 8 week
|
By measuring markers of vascular inflammation (adiponectin, leptin, endothelin-1, angiotensin II and 8-isoprostane).
|
8 week
|
Inflammation
Time Frame: 8 weeks
|
By measuring a marker of inflammation (tumor necrosis factor-α [TNF-α]).
|
8 weeks
|
Oxidative Stress
Time Frame: 8 weeks
|
By measuring markers of oxidative stress (superoxide dismutase [SOD], nitrate/nitrite [NOx], ET-1, angiotensin II, 8-isoprostane, MDA, and oxidized LDL).
|
8 weeks
|
Arterial Stiffness
Time Frame: 8 Week
|
By measuring the augmentation index and arterial stiffness at rest and during physiological stress (handgrip exercise and post-exercise muscle ischemia).
|
8 Week
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Arturo Figueroa, MD, PhD, Florida State University
- Principal Investigator: Sarah A Johnson, PhD, RD, CSO, Florida State University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 021259
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Pressure
-
SE HealthCentre for Aging and Brain Health InnovationCompletedHypertension | Blood Pressure | Hypotension | High Blood Pressure | Low Blood PressureCanada
-
DongGuk UniversityActive, not recruitingHypertension | Blood Pressure | Ambulatory Blood Pressure | Home Blood Pressure MeasurementKorea, Republic of
-
University of JordanCompletedBlood Pressure | Heart Rate | Airway PressureJordan
-
ROX Medical, Inc.CompletedHypertension | Blood Pressure, High | Blood Pressure, Resistant | Blood Pressure, UncontrolledUnited Kingdom, Netherlands, Belgium
-
Istituto Auxologico ItalianoRecruitingArterial Hypertension | Ambulatory Blood Pressure Monitoring | Blood Pressure Determination | Home Blood Pressure MonitoringItaly
-
RadiRad Co., Ltd.Hualien Tzu Chi General HospitalNot yet recruitingBlood Pressure
-
Riphah International UniversityRecruiting
-
GE HealthcareNot yet recruiting
-
Guangdong Provincial People's HospitalRecruiting
-
Guangdong Provincial People's HospitalRecruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States